ALBERTDAVD - Albert David

📊 NSE: ALBERTDAVD 🏢 Pharmaceuticals - Indian - Bulk Drugs & Formln 📅 Last Updated: 12/13/2025 18:07

💰 Financial Performance

Revenue Growth by Segment

The company operates in a single pharmaceutical segment. Total revenue from operations for FY25 was INR 345.76 Cr, representing a decline of 4.61% compared to INR 362.46 Cr in FY24.

Geographic Revenue Split

Not disclosed in available documents as the company operates in a single segment and does not segregate by geographical presence.

Profitability Margins

Profitability saw a significant decline in FY25. Operating Profit Margin turned negative at -3.61% from 4.95% in FY24. Net Profit Margin dropped to 5.01% from 20.93% YoY. Return on Net Worth decreased by 18.86 percentage points to 6.27% from 25.13%.

EBITDA Margin

EBITDA margin for FY25 was 9.43% (INR 32.61 Cr), a sharp decline of 68.77% from INR 104.43 Cr (28.81% margin) in FY24 due to increased employee and distribution expenses.

Capital Expenditure

Historical capital expenditure for the half-year ended September 30, 2025, was INR 6.28 Cr, primarily for upgrading facilities as per Revised Schedule-M.

Credit Rating & Borrowing

CARE A; Negative (Outlook revised from Stable in June 2025). Borrowings increased to INR 39.52 Cr as of September 2025 from INR 10.05 Cr in March 2025, leading to a 366.97% increase in the Debt-Equity ratio to 0.03.

⚙️ Operational Drivers

Capacity Expansion

The company is currently upgrading its manufacturing units to comply with Revised Schedule-M standards to meet market demand and improve cost control.

Manufacturing Efficiency

Efforts are being made to adopt the latest technology to upgrade units for effective cost control; however, specific utilization percentages were not disclosed.

Logistics & Distribution

Sales and distribution costs increased significantly in FY25 as part of a strategy to expand market reach and product penetration.

📈 Strategic Growth

Expected Growth Rate

9.80%

Growth Strategy

Growth is targeted through upgrading facilities to Revised Schedule-M standards, R&D focus on new molecules and drug delivery systems, and increased spending on sales and distribution to penetrate new markets.

Products & Services

Placenta-based drugs and other pharmaceutical formulations.

Brand Portfolio

Albert David.

New Products/Services

R&D team is working on new molecules to strengthen the product pipeline; expected revenue contribution was not disclosed.

Market Expansion

The company is expanding its market reach through higher sales and distribution costs, though specific target regions were not named.

Market Share & Ranking

The company holds an established market position in placenta-based drugs.

🌍 External Factors

Industry Trends

The pharmaceutical industry is highly challenging with a focus on quality and drug delivery systems. The industry is evolving towards stricter manufacturing standards like Revised Schedule-M.

Competitive Landscape

The company operates in a highly challenging pharmaceutical market with moderate scale of operations compared to larger peers.

Competitive Moat

The moat is built on an established market position in placenta-based drugs and a strong distribution network, which are sustainable due to the specialized nature of these products.